Results 101 to 110 of about 1,250,673 (409)

The shape and size of hydroxyapatite particles dictate inflammatory responses following implantation

Scientific Reports, 2017
The extent of regeneration following biomaterial implantation is dependent on the microenvironment surrounding the implant. Since implant composition can have a profound effect on inflammation, it is essential to understand this process as a non ...
Filipa Lebre, Rukmani Sridharan, Michael J. Sawkins, Daniel J. Kelly, Fergal J. O’Brien, Ed C. Lavelle   +5 more
doaj   +1 more source

Advax, a Delta Inulin Microparticle, Potentiates In-built Adjuvant Property of Co-administered Vaccines

EBioMedicine, 2017
Advax, a delta inulin-derived microparticle, has been developed as an adjuvant for several vaccines. However, its immunological characteristics and potential mechanism of action are yet to be elucidated.
Masayuki Hayashi, Taiki Aoshi, Yasunari Haseda, Kouji Kobiyama, Edward Wijaya, Noriyuki Nakatsu, Yoshinobu Igarashi, Daron M. Standley, Hiroshi Yamada, Yoshikazu Honda-Okubo, Hiromitsu Hara, Takashi Saito, Toshiyuki Takai, Cevayir Coban, Nikolai Petrovsky, Ken J. Ishii   +15 more
doaj   +1 more source

Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination.

ACS Nano, 2018
Tumor vaccines for cancer prevention and treatment have attracted tremendous interests in the area of cancer immunotherapy in recent years. In this work, we present a strategy to construct cancer vaccines by encapsulating immune-adjuvant nanoparticles ...
Rong Yang, Jun Xu, Ligeng Xu, Xiaoqi Sun, Qian Chen, Yuhuan Zhao, Rui Peng, Zhuang Liu   +7 more
semanticscholar   +1 more source

Screening vaccine formulations for biological activity using fresh human whole blood. [PDF]

, 2014
Understanding the relevant biological activity of any pharmaceutical formulation destined for human use is crucial. For vaccine-based formulations, activity must reflect the expected immune response, while for non-vaccine therapeutic agents, such as ...
Aboutorabian, Sepideh, Ausar, Salvador F, Brookes, Roger H, Dockrell, Hazel M, Ha, Yukyung, Hakimi, Jalil, Hasija, Manvi, Rahman, Nausheen, Smith, Steven G, Todryk, Stephen M   +9 more
core   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

CTNI-33. CSNO2012001 STUDY: A PHASE III TRIAL ON ADJUVANT TEMOZOLOMIDE CHEMOTHERAPY WITH OR WITHOUT INTERFERON-ALPHA IN NEWLY DIAGNOSED HIGH-GRADE GLIOMAS [PDF]

, 2022
Zhongping Chen, Chengcheng Guo, JianGen Chen   +2 more
openalex   +1 more source

Engineered immunogen binding to alum adjuvant enhances humoral immunity

Nature Medicine, 2020
Adjuvants are central to the efficacy of subunit vaccines. Aluminum hydroxide (alum) is the most commonly used vaccine adjuvant, yet its adjuvanticity is often weak and mechanisms of triggering antibody responses remain poorly understood.
Tyson J. Moyer, Y. Kato, W. Abraham, Jason Y. H. Chang, Daniel W. Kulp, N. Watson, H. Turner, Sergey Menis, R. Abbott, Jinal Bhiman, M. Melo, Hayley Simon, S. Herrera-de la Mata, Shu Liang, G. Seumois, Yash Agarwal, Na Li, D. Burton, A. Ward, W. Schief, S. Crotty, D. Irvine   +21 more
semanticscholar   +1 more source

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. [PDF]

, 2013
Data characterizing demographics, treatment patterns, and clinical outcomes in black patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) are limited.
Abidoye, Oyewale O, Brufsky, Adam M, Kaufman, Peter A, Mayer, Musa, Rugo, Hope S, Tripathy, Debu, Ulcickas Yood, Marianne, Yardley, Denise A, Yoo, Bongin   +8 more
core   +1 more source

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

Molecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien   +35 more
wiley   +1 more source

PB2114: TREATMENT RESULTS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FROM HIGH-RISK GROUP

HemaSphere, 2022
K. Filonenko, I. Kriachok, A. Martynchyk, I. Titorenko, Y. Stepanishyna, O. Aleksyk, K. Ukianchenko, I. Pastushenko, Y. Kushchevyy, O. Novosad, O. Karnabeda, I. Diagil, V. Kozlov   +12 more
doaj   +1 more source